Literature DB >> 2898767

Components required for in vitro cleavage and polyadenylation of eukaryotic mRNA.

J McLauchlan1, C L Moore, S Simpson, J B Clements.   

Abstract

We have studied in vitro cleavage/polyadenylation of precursor RNA containing herpes simplex virus type 2 poly A site sequences and have analyzed four RNA/protein complexes which form during in vitro reactions. Two complexes, A and B, form extremely rapidly and are then progressively replaced by a third complex, C which is produced following cleavage and polyadenylation of precursor RNA. Substitution of ATP with cordycepin triphosphate prevents polyadenylation and the formation of complex C however a fourth complex, D results which contains cleaved RNA. A precursor RNA lacking GU-rich downstream sequences required for efficient cleavage/polyadenylation fails to form complex B and produces a markedly reduced amount of complex A. As these GU-rich sequences are required for efficient cleavage, this establishes a relationship between complex B formation and cleavage/polyadenylation of precursor RNA in vitro. The components required for in vitro RNA processing have been separated by fractionation of the nuclear extract on Q-Sepharose and Biorex 70 columns. A Q-Sepharose fraction forms complex B but does not process RNA. Addition of a Biorex 70 fraction restores cleavage activity at the poly A site but this fraction does not appear to contribute to complex formation. Moreover, in the absence of polyethylene glycol, precursor RNA is not cleaved and polyadenylated, however, complexes A and B readily form. Thus, while complex B is necessary for in vitro cleavage and polyadenylation, it may not contain all the components required for this processing.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898767      PMCID: PMC336770          DOI: 10.1093/nar/16.12.5323

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  32 in total

1.  A sequence downstream of A-A-U-A-A-A is required for formation of simian virus 40 late mRNA 3' termini in frog oocytes.

Authors:  L Conway; M Wickens
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

2.  Inhibition of RNA cleavage but not polyadenylation by a point mutation in mRNA 3' consensus sequence AAUAAA.

Authors:  C Montell; E F Fisher; M H Caruthers; A J Berk
Journal:  Nature       Date:  1983 Oct 13-19       Impact factor: 49.962

3.  Site-specific polyadenylation in a cell-free reaction.

Authors:  C L Moore; P A Sharp
Journal:  Cell       Date:  1984-03       Impact factor: 41.582

4.  Requirement of a downstream sequence for generation of a poly(A) addition site.

Authors:  M A McDevitt; M J Imperiale; H Ali; J R Nevins
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

5.  Regulation of adenovirus-2 gene expression at the level of transcriptional termination and RNA processing.

Authors:  J R Nevins; M C Wilson
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

6.  Recognition of cap structure in splicing in vitro of mRNA precursors.

Authors:  M M Konarska; R A Padgett; P A Sharp
Journal:  Cell       Date:  1984-10       Impact factor: 41.582

7.  Normal and mutant human beta-globin pre-mRNAs are faithfully and efficiently spliced in vitro.

Authors:  A R Krainer; T Maniatis; B Ruskin; M R Green
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

8.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

9.  Alpha-thalassaemia caused by a polyadenylation signal mutation.

Authors:  D R Higgs; S E Goodbourn; J Lamb; J B Clegg; D J Weatherall; N J Proudfoot
Journal:  Nature       Date:  1983 Nov 24-30       Impact factor: 49.962

10.  Specific pre-cleavage and post-cleavage complexes involved in the formation of SV40 late mRNA 3' termini in vitro.

Authors:  D Zarkower; M Wickens
Journal:  EMBO J       Date:  1987-12-20       Impact factor: 11.598

View more
  9 in total

1.  Unusual aspects of in vitro RNA processing in the 3' regions of the GAL1, GAL7, and GAL10 genes in Saccharomyces cerevisiae.

Authors:  P P Sadhale; T Platt
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

2.  Potential role of poly(A) polymerase in the assembly of polyadenylation-specific RNP complexes.

Authors:  M P Terns; S T Jacob
Journal:  Nucleic Acids Res       Date:  1991-01-25       Impact factor: 16.971

3.  A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability.

Authors:  I M Kennedy; J K Haddow; J B Clements
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

4.  A multicomponent complex is required for the AAUAAA-dependent cross-linking of a 64-kilodalton protein to polyadenylation substrates.

Authors:  J Wilusz; T Shenk; Y Takagaki; J L Manley
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

5.  Sumoylation modulates the assembly and activity of the pre-mRNA 3' processing complex.

Authors:  Vasupradha Vethantham; Nishta Rao; James L Manley
Journal:  Mol Cell Biol       Date:  2007-10-08       Impact factor: 4.272

6.  Analysis of human papillomavirus type 16 late mRNA 3' processing signals in vitro and in vivo.

Authors:  I M Kennedy; J K Haddow; J B Clements
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

7.  Role of poly(A) polymerase in the cleavage and polyadenylation of mRNA precursor.

Authors:  M P Terns; S T Jacob
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

8.  Approaches to maximizing stable expression of alpha 1-antitrypsin in transformed CHO cells.

Authors:  T Paterson; J Innes; S Moore
Journal:  Appl Microbiol Biotechnol       Date:  1994-01       Impact factor: 4.813

9.  Transcriptional termination sequences in the mouse serum albumin gene.

Authors:  Steven West; Kenneth Zaret; Nick J Proudfoot
Journal:  RNA       Date:  2006-04       Impact factor: 4.942

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.